The inhibition of PARP has emerged as a therapeutic approach in tumors that are intrinsically deficient in DNA repair, such as_BRCA1/2-mutation-positive breast or ovarian cancers.
Particularly in ovarian cancer, where for decades chemotherapy has been the main current treatment, these agents have revolutionized the treatment algorithm.
In this eBook, DRG Oncology expert Carolina do Pazo shares her perspective on emerging therapies and trends shaping the future of the PARP inhibitors landscape.
Key topics covered include:
- Current leading therapies
- Emerging players, agents and trials to watch
- Disease management and access issues
- Perspectives from oncologist KOLs
- Takeaways for biopharma strategists